nach oben

Wiener klinische Wochenschrift

Erschienen in:

01.08.2012 | original article

The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease

verfasst von: Tugrul Purnak, MD, Yavuz Beyazit, MD, Asso. Prof. Ersan Ozaslan, MD, Cumali Efe, MD, Merve Hayretci, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2012

Einloggen, um Zugang zu erhalten

Abstract

Background and aim

Nonalcoholic fatty liver diseases (NAFLD) are a clinical spectrum of disorders, of which nonalcoholic steatohepatitis (NASH) is the most strongly associated with inflammation. Inflammation is a known risk factor for low bone mass in the body. The primary goal of the present study was to evaluate the association between bone mineral density and liver function in patients with NASH.

Materials and methods

Consenting patients with a diagnosis of NAFLD were included in the study. Extent of fatty change was graded based on ultrasonographic appearance (Grade 1, mild; Grade 2, moderate; Grade 3, severe). Bone mineral density was measured using the dual-energy x-ray absorptiometry method. ALT and hs-CRP were considered as noninvasive marker of NASH. According to ALT levels, patients were divided into two subgroups.

Results

A total of 102 patients with NAFLD and 54 healthy controls participated in the study. None of the patients with NAFLD had an abnormal bone mineral density. Furthermore, there was no difference between groups with regard to serum vitamin D levels. A subgroup analysis revealed that female patients with elevated serum ALT level had significantly lower bone mineral densities and higher hsCRP levels than female patients with normal ALT levels. The difference in vitamin D levels and body mass indices between the same subgroups was statistically insignificant.

Conclusions

Simple steatosis of the liver does not affect bone mineral density. However, in a subgroup of patients with NAFLD, the presence of elevated serum ALT and hs-CRP levels, which are suggestive of NASH, was associated with lower bone mineral densities. Better understanding of the biological basis and the complex interactions between NAFLD and bone mass may help guide the clinical management of bone diseases associated with inflammation of the liver.

Vorheriger Artikel Serum lactate level predict mortality in elderly patients with cirrhosis

Nächster Artikel Measuring quality of life with the German Osteoporosis Quality of Life Questionnaire in women with osteoporosis

Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863–9.PubMedCrossRef

Duvnjak M, Lerotic I, Barsic N,et al. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 2007;13:4539–50.PubMed

Vuppalanchi R, Chalasani N. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management. Hepatology 2009;49:306–17PubMedCrossRef

Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology 2005;42:650–6.PubMedCrossRef

Kogiso T, Moriyoshi Y, Shimizu S, Nagahara H, Shiratori K. High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the akaike Information criterion scoring system in the general Japanese population. J Gastroenterol. 2009;44:313–21.PubMedCrossRef

Kinjo M, Setoguchi S, Solomon DH. Bone mineral density in adults with the metabolic syndrome: Analysis in a population-based US sample. J Clin Endocrinol Metab. 2007;92:4161–4.PubMedCrossRef

Kelman A, Lane NE. The management of secondary osteoporosis. Best Pract Res Clin Rheumatol. 2005;19:1021–37.PubMedCrossRef

Kotake S, Udagawa N, Hakoda M,et al. Activated human T cells directly induce osteoclastogenesis from human monocytes: Possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 2001;44:1003–12.PubMedCrossRef

Smith BJ, Lerner MR, Bu SY,et al. Systemic bone loss and induction of coronary vessel disease in a rat model of chronic inflammation. Bone 2006;38:378–6.PubMedCrossRef

10.

Caetano-Lopes J, Canhao H, Fonseca JE. Osteoimmunology—the hidden immune regulation of bone. Autoimmun Rev. 2009;8:250–5.

11.

Tilg H, Moschen AR, Kaser A, Pines A, Dotan I. Gut inflammation and osteoporosis: Basic and clinical concepts. Gut 2008;57:684–4.PubMedCrossRef

12.

Lacativa PG, Farias ML. Osteoporosis and inflammation. Arq Bras Endocrinol Metabol. 2010;54:123–2.PubMedCrossRef

13.

Tilg H. The role of cytokines in non-alcoholic fatty liver disease. Dig Dis. 2010;28:179–85.PubMedCrossRef

14.

Ndumele CE, Nasir K, Conceicao RD,et al. Hepatic steatosis, obesity, and the metabolic syndrome are independently and additively associated with increased systemic inflammation. Arterioscler Thromb Vasc Biol. 2011;31(8):1927–32.PubMedCrossRef

15.

Matthews DR, Hosker JP, Rudenski AS,et al. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–19.PubMedCrossRef

16.

Prati D, Taioli E, Zanella A,et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1–10.PubMed

17.

Bouillon R, Auwerx J, Dekeyser L,et al. Serum vitamin D metabolites and their binding protein in patients with liver cirrhosis. J Clin Endocrinol Metab. 1984;59:86–9.PubMedCrossRef

18.

Skinner RK, Sherlock S, Long RG, Wilis MR. 25-Hydroxylation of vitamin D in primary biliary cirrhosis. Lancet 1977;1:720–1PubMedCrossRef

19.

Nakchbandi IA, Van Der Merwe SW. Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:660–70PubMedCrossRef

20.

Hwang DK, Choi HJ. The relationship between low bone mass and metabolic syndrome in Korean women. Osteoporos Int. 2009;21(3):425–31.PubMedCrossRef

21.

Marchesini G, Marzocchi R. Metabolic syndrome and NASH. Clin Liver Dis. 2007;11:105–17ix.PubMedCrossRef

22.

Leslie WD, Bernstein CN, Leboff MS. AGA technical review on osteoporosis in hepatic disorders. Gastroenterology 2003;125:941–66.PubMedCrossRef

23.

Schiefke I, Fach A, Wiedmann M,et al. Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol. 2005;11:1843–7.PubMed

24.

Guggenbuhl P, Deugnier Y, Boisdet JF,et al. Bone mineral density in men with genetic hemochromatosis and HFE gene mutation. Osteoporos Int. 2005;16:1809–14.PubMedCrossRef

25.

Hegedus D, Ferencz V, Lakatos PL,et al. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease. J Bone Miner Res. 2002;17:1961–7.CrossRef

26.

Crippin JS, Jorgensen RA, Dickson ER, Lindor KD. Hepatic osteodystrophy in primary biliary cirrhosis: Effects of medical treatment. Am J Gastroenterol. 1994;89:47–50.PubMed

27.

Levy C, Lindor KD. Management of osteoporosis, fat-soluble vitamin deficiencies, and hyperlipidemia in primary biliary cirrhosis. Clin Liver Dis. 2003;7:901–0.PubMedCrossRef

28.

Bauer DC, Sklarin PM, Stone KL,et al. Biochemical markers of bone turnover and prediction of hip bone loss in older women: The study of osteoporotic fractures. J Bone Miner Res. 1999;14:1404-0.PubMedCrossRef

29.

Bernstein CN, Leslie WD, Leboff MS. AGA technical review on osteoporosis in gastrointestinal diseases. Gastroenterology 2003;124:795–41.PubMedCrossRef

30.

Rogers A, Hannon RA, Eastell R. Biochemical markers as predictors of rates of bone loss after menopause. J Bone Miner Res. 2000;15:1398–04.PubMedCrossRef

31.

Mishra P, Younossi ZM. Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol. 2007;102:2716–7.PubMedCrossRef

32.

Babali A, Cakal E, Purnak T,et al. Serum alpha-fetoprotein levels in liver steatosis. Hepatol Int. 2009;3(4):551–5.PubMedCrossRef

33.

Hamaguchi M, Kojima T, Itoh Y, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am J Gastroenterol. 2007;102:2708–15.PubMedCrossRef

Titel: The evaluation of bone mineral density in patients with nonalcoholic fatty liver disease
verfasst von: Tugrul Purnak, MD
Yavuz Beyazit, MD
Asso. Prof. Ersan Ozaslan, MD
Cumali Efe, MD
Merve Hayretci, MD
Publikationsdatum: 01.08.2012
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 15-16/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-012-0211-4

Springer Medizin Österreich

Abstract

Background and aim

Materials and methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 15-16/2012

OeGIM-Homepage – Additivfächer

Serum lactate level predict mortality in elderly patients with cirrhosis

Concomitant use of beta-1 adrenoreceptor blocker and norepinephrine in patients with septic shock

43. Jahrestagung der Österreichischen Gesellschaft für Innere Medizin

Central venous to arterial pCO2 difference in cardiogenic shock

Is second eye phacoemulsification really more painful?